EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access

Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial

K Rachael Parks iD, Zoe Moodie iD, Mary A Allen iD, Catherine Yen, Briana D Furch iD, Kellie J MacPhee iD, Gabriel Ozorowski iD, Jack Heptinstall iD, William O Hahn, Zihan Zheng iD, Huiyin Lu, Shannon Grant und 38 weitere

Science Translational Medicine · 30.07.2025 · 17 (809)

DOI: 10.1126/scitranslmed.ady6831 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Science Translational Medicine, erschienen am 30.07.2025. Verfasst von K Rachael Parks und 49 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, AIDS Vaccines, RNA, Messenger, Vaccination. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, Bill & Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mRNA technology might accelerate development of an urgently needed preventive human immunodeficiency virus (HIV) vaccine. We evaluated the safety and immunogenicity of three mRNA-encoded envelope trimers, including two doses of soluble and membrane-anchored forms, in a randomized, open-label, phase 1 clinical trial. Vaccines were generally well tolerated, although 6.5% (7 of 108) of participants developed urticaria, a higher proportion than seen with other mRNA vaccines. mRNA-encoded trimers induced strong envelope-specific B and T cell responses. Immunization with membrane-anchored trimers, intended to obscure epitopes at the trimer base targeted by nonneutralizing antibodies, reduced the frequency of base-binding serum antibodies in comparison with soluble trimers. Three immunizations elicited autologous tier 2 serum neutralizing antibodies in 80% of vaccinees receiving the membrane-anchored trimers, in contrast to only 4% receiving the soluble trimer. Thus, with demonstration of more favorable safety, mRNA-encoded membrane-anchored HIV envelope trimers represent a promising platform for HIV vaccine clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingAIDS VaccinesRNA, MessengerVaccinationenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesProtein MultimerizationHumansFemaleMaleAdultHIV InfectionsHIV-1Middle Aged

Substanzen

Antibodies, NeutralizingAIDS VaccinesRNA, Messengerenv Gene Products, Human Immunodeficiency VirusHIV Antibodies

Autor:innen und Institutionen

  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
  • Department of Integrative, Structural, and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.
  • Center for Human Systems Immunology, Departments of Surgery, Immunology, Molecular Genetics, and Microbiology, Duke University, Durham, NC 27701, USA.
  • Department of Medicine, University of Washington, Seattle, WA 98195, USA.
  • Duke University Medical Center, Durham, NC 27701, USA.

ORCID-Profile: K Rachael Parks, Zoe Moodie, Mary A Allen, Briana D Furch, Kellie J MacPhee, Gabriel Ozorowski, Jack Heptinstall, Zihan Zheng, Elize Domin, Michael O Duff, Aaron Seese, Lamar Ballweber-Fleming, Wen-Hsin Lee, Christopher A Cottrell, Alessia Liguori, Erik Georgeson, Nushin Alavi, Nicole Phelps, Kelly E Seaton, Kristen W Cohen, Kajari Mondal, Dagna S Laufer, James G Kublin, Andrew B Ward, Ollivier Hyrien, Stephen C De Rosa, Sunny Himansu, Caroline Reuter, Georgia D Tomaras, David Montefiori, Stephen R Walsh, Ian Frank, Magdalena E Sobieszczyk, Paul A Goepfert, Kathryn E Stephenson, Hong Van Tieu, Michael C Keefer, Jesse Clark, Sharon A Riddler, William R Schief, M Juliana McElrath

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • Bill & Melinda Gates Foundation

Zitieren

APA

Parks, K. R., Moodie, Z., Allen, M. A., Yen, C., Furch, B. D., MacPhee, K. J., Ozorowski, G., Heptinstall, J., Hahn, W. O., Zheng, Z., Lu, H., Grant, S., Domin, E., Duff, M. O., Seese, A., Marini-Macouzet, C., Ballweber-Fleming, L., Lee, W. H., Cottrell, C. A., …, & McElrath, M. J. (2025). Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Science Translational Medicine, 17(809). https://doi.org/10.1126/scitranslmed.ady6831

Vancouver

Parks KR, Moodie Z, Allen MA, Yen C, Furch BD, MacPhee KJ, et al. Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Science Translational Medicine. 2025;17(809). doi:10.1126/scitranslmed.ady6831

BibTeX
@article{Parks2025,
  author = {Parks, K Rachael and Moodie, Zoe and Allen, Mary A and Yen, Catherine and Furch, Briana D and MacPhee, Kellie J and Ozorowski, Gabriel and Heptinstall, Jack and Hahn, William O and Zheng, Zihan and Lu, Huiyin and Grant, Shannon and Domin, Elize and Duff, Michael O and Seese, Aaron and Marini-Macouzet, Constanza and Ballweber-Fleming, Lamar and Lee, Wen-Hsin and Cottrell, Christopher A and Liguori, Alessia and Georgeson, Erik and Alavi, Nushin and Kubitz, Michael and Phelps, Nicole and Seaton, Kelly E and Cohen, Kristen W and Anderson, Maija A and Mondal, Kajari and Laufer, Dagna S and Kublin, James G and Ward, Andrew B and Hyrien, Ollivier and De Rosa, Stephen C and Himansu, Sunny and Leav, Brett and Reuter, Caroline and Tomaras, Georgia D and Montefiori, David and Walsh, Stephen R and Frank, Ian and Sobieszczyk, Magdalena E and Goepfert, Paul A and Stephenson, Kathryn E and Baden, Lindsey R and Van Tieu, Hong and Keefer, Michael C and Clark, Jesse and Riddler, Sharon A and Schief, William R and McElrath, M Juliana},
  title = {Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial},
  journal = {Science Translational Medicine},
  year = {2025},
  volume = {17},
  number = {809},
  doi = {10.1126/scitranslmed.ady6831}
}
Kostenlos starten →